IO Biotech, Inc. (IOBT)Healthcare | Biotechnology | Copenhagen, Denmark |
USD
Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 10:22 p.m. UTC
Extremely high risk: IO Biotech is in active Chapter 7 liquidation following FDA and strategic rejection, with price collapsing from $0.17 to $0.01 in a week; the model predicts a further -17.5% decline, making it a clear sell/avoid unless liquidation bounces occur. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.658560 |
| AutoARIMA | 0.890757 |
| AutoETS | 1.110976 |
| MSTL | 1.125323 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 18% |
| H-stat | 158.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1988.913 |
| Market Cap | 3,453,544 |
| Forward P/E | -0.13 |
| Beta | 0.89 |
| Website | https://www.iobiotech.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9897511 |
| Address1 | Ole MaalOees Vej 3 |
| Address2 | Copenhagen N |
| All Time High | 17.88 |
| All Time Low | 0.006 |
| Ask | 0.0422 |
| Ask Size | 600 |
| Average Daily Volume10 Day | 75,805,593 |
| Average Volume | 21,542,690 |
| Average Volume10Days | 75,805,593 |
| Beta | 0.888 |
| Bid | 0.0415 |
| Bid Size | 100 |
| Book Value | 0.013 |
| City | Copenhagen |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Denmark |
| Currency | USD |
| Current Price | 0.048 |
| Current Ratio | 2.011 |
| Date Short Interest | 1,773,360,000 |
| Day High | 0.055 |
| Day Low | 0.0277 |
| Debt To Equity | 1,988.913 |
| Ebitda | -91,802,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.13 |
| Enterprise Value | -11,955,019 |
| Exchange | NMS |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 0.2349162 |
| Fifty Two Week High | 2.79 |
| Fifty Two Week Low | 0.006 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,636,119,000 |
| Float Shares | 38,307,722 |
| Forward Eps | -0.36 |
| Forward P E | -0.13333333 |
| Free Cashflow | -49,063,376 |
| Full Time Employees | 80 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Held Percent Insiders | 0.06627 |
| Held Percent Institutions | 0.46738 |
| Implied Shares Outstanding | 71,948,842 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,735,603,200 |
| Long Business Summary | IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark. On March 31, 2026, IO Biotech, Inc., along with its affiliate, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. |
| Long Name | IO Biotech, Inc. |
| Market Cap | 3,453,544 |
| Max Age | 86,400 |
| Message Board Id | finmb_1685354464 |
| Most Recent Quarter | 1,759,190,400 |
| Net Income To Common | -88,349,000 |
| Next Fiscal Year End | 1,767,139,200 |
| Non Diluted Market Cap | 437,448 |
| Number Of Analyst Opinions | 2 |
| Open | 0.0288 |
| Operating Cashflow | -80,996,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 45 70 70 29 80 |
| Previous Close | 0.0 |
| Price Hint | 4 |
| Price To Book | 3.6923077 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.729 |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Regular Market Day High | 0.055 |
| Regular Market Day Low | 0.0277 |
| Regular Market Open | 0.0288 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 469,191,612 |
| Return On Assets | -0.88579005 |
| Return On Equity | -2.40484 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 71,948,842 |
| Shares Percent Shares Out | 0.0392 |
| Shares Short | 2,820,245 |
| Shares Short Previous Month Date | 1,770,940,800 |
| Shares Short Prior Month | 4,262,939 |
| Short Name | IO Biotech, Inc. |
| Short Percent Of Float | 0.0749 |
| Short Ratio | 2.06 |
| Symbol | IOBT |
| Target High Price | 4.0 |
| Target Low Price | 0.36 |
| Target Mean Price | 2.18 |
| Target Median Price | 2.18 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 30,664,000 |
| Total Cash Per Share | 0.426 |
| Total Debt | 18,119,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -0.23 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 0.88830656 |
| Underlying Symbol | IOBT |
| Uuid | ea2848e4-aa90-3bf4-82a5-9ce691c6a8c0 |
| Volume | 469,191,612 |
| Website | https://www.iobiotech.com |
| Zip | 2,200 |